Two French companies updated
their IPO terms last week, as bioprocessing play Deinove and autoimmune
and inflammation company Neovacs S.A. aim to complete their deals over
the next two weeks.
Deinove is using deinococci
bacteria to develop technologies to make biofuels and antibiotics, which are in
discovery. It is seeking to raise about €12 million ($16.2
million) through the sale of 1.4 million shares at